Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05946824 · ClinicalTrials.gov registry record · Phase 2
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
A Phase 2 study of Recurrent Prostate Cancer After Surgery, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05946824 is a Phase 2 study of Recurrent Prostate Cancer After Surgery that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05946824, a Phase 2 study of Recurrent Prostate Cancer After Surgery, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the health care system. Stereotactic body radiation (SBRT) is a radiation technique in which large doses are delivered over a short period of time. To date there is extremely limited evidence in SBRT for recurrent prostate cancer after surgery, with a significantly growing body of evidence for primary SBRT treatment of prostate cancer in men who opt for non-surgical upfront treatment. Additionally, advances in imaging have allowed better detection of the site of recurrence, and novel artificial intelligence aided daily-adaptive radiation therapy have allowed more precise delivery of radiation doses. This study seeks to evaluate the role of Daily-Adaptive with AI-assisted SBRT in the post operative setting utilizing Ethos Plan Adaptive technology in attempt to maintain control and minimize side effects.
Conditions Studied
Interventions
- RADIATION Daily-adaptive Stereotactic Body Radiation Therapy
Study Locations (1)
New York
- Wilmot Cancer Institute - Dept of Radiation Oncology - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2028-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05946824
The ClinicalTrials.gov registry entry for NCT05946824 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Prostate Cancer After Surgery appearing as the primary indexed condition, and to 1 intervention - of which Daily-adaptive Stereotactic Body Radiation Therapy is the first listed.
NCT05946824 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05946824 about?
NCT05946824 is a clinical study titled "This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.". There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the health care system. Stereotactic body radiation (SBRT) is a radiation t...
What is the current status of trial NCT05946824?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-12-14. Estimated completion is 2028-11-24.
What conditions does trial NCT05946824 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer After Surgery.
What interventions are being tested in trial NCT05946824?
The interventions under investigation include: Daily-adaptive Stereotactic Body Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05946824?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05946824 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.